To make the therapy safer and more adaptable, UChicago researchers developed a new “split” system called GA1CAR. This uses ...

During a live event, Thomas G. Martin, MD, discussed updated findings from the CARTITUDE-1 trial of cilta-cel and what they signify for patients with no disease progression at 5 years.

March Biosciences (March Bio), a clinical stage biotechnology company developing cell therapies for hard-to-treat cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted ...

Data demonstrate efficacy and durability of vispa-cel, an allogeneic anti-CD19 CAR-T cell therapy, are on par with autologous CAR-T cell ...

The discovery of new cancer cells with a switched-on gene called ZBTB16 is a breakthrough in childhood blood cancer research.

Glioblastoma (GBM), the most aggressive primary brain tumor, continues to portend a poor prognosis with median survival under ...

“Utilizing real-world data, technology, strategic solutions, and cross-departmental partnerships will help ensure equitable access, so the right member receives the right drug at the right time and ...

Artiva remains on track to share initial clinical response data and conduct U.S. Food and Drug Administration (FDA) regulatory interactions to align on pivotal trial design for AlloNK in refractory ...

Gilead Sciences' Kite Pharma is doubling down on in vivo CAR-T, this time inking a deal worth up to $1.64 billion biobucks with Chinese biotech Pregene Biopharma. Kite has paid out $120 million ...

Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that it will hold a webcast beginning at ...